Ipilimumab-Induced Adrenalitis: A Possible Pitfall in 18F-FDG-PET/CT.
- Bacanovic S From the *Department of Medical Radiology, Division of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland; †Department of Medical Radiology, Divisions of Nuclear Medicine and Neuroradiology, University Hospital Zurich, Zurich, Switzerland; and ‡Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
- Burger IA
- Stolzmann P
- Hafner J
- Huellner MW
- 2015-07-13
Published in:
- Clinical nuclear medicine. - 2015
Adrenocortical Hyperfunction
Aged
Antibodies, Monoclonal
Antineoplastic Agents
False Positive Reactions
Fluorodeoxyglucose F18
Humans
Ipilimumab
Male
Melanoma
Multimodal Imaging
Neoplasm Metastasis
Positron-Emission Tomography
Radiopharmaceuticals
Tomography, X-Ray Computed
English
Ipilimumab is a monoclonal antibody against the inhibitory CTLA-4 receptor expressed on T cells. It provokes an upregulation of the immune system. This substance was approved by the US Food and Drug Administration in 2011 and is since increasingly used as a targeted therapeutic approach for metastasized melanoma. Ipilimumab is known to cause neuroendocrine disorders, such as hypophysitis and adrenal insufficiency. Our case of a 79-year-old patient represents an important imaging pitfall. Imaging findings of newly symmetrically and smoothly enlarged, hypermetabolic adrenal glands in the setting of previous ipilimumab therapy represent drug-induced adrenalitis and not metastatic disease.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1097/RLU.0000000000000887
- PMID 26164177
- Persistent URL
- https://sonar.ch/global/documents/298491
Statistics
Document views: 28
File downloads:
- Full-text: 0